Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Izraēla - angļu - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine dr teva is indicated for:- the treatment of major depressive episodes. - the management of neuropathic pain associated with diabetic peripheral neuropathy. - the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia. - the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low ‎back pain (clbp) and chronic pain due to osteoarthritis.

Izraēla - angļu - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine dr teva is indicated for:- the treatment of major depressive episodes. - the management of neuropathic pain associated with diabetic peripheral neuropathy. - the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia. - the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low ‎back pain (clbp) and chronic pain due to osteoarthritis.

Izraēla - angļu - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Izraēla - angļu - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - gastro resistant capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine sandoz is indicated for - the treatment of major depressive episodes.- the management of neuropathic pain associated with diabetic peripheral neuropathy.- the treatment of generalized anxiety disorder (gad).- the management of fibromyalgia.- the management of chronic muscoskeletal pain when other therapies have failed or are contra-indicated. this has been established in studies in patients with chronic low back pain (clbp) and chronic pain due to osteoarthritis.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly is indicated in adults for:treatment of major depressive disordertreatment of diabetic peripheral neuropathic paintreatment of generalised anxiety disorderduloxetine lilly is indicated in adults.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: • major depressive disorder [see clinical studies (14.1)] • generalized anxiety disorder [see clinical studies (14.2)] • diabetic peripheral neuropathy [see clinical studies (14.3)] • chronic musculoskeletal pain [see clinical studies (14.5)] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increa

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - duloxetine delayed-release capsules are indicated for the treatment of major depressive disorder (mdd). the efficacy of duloxetine was established in four short term and one maintenance trial in adults [see clinical studies (14.1) ]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. duloxetine delayed-release capsules are indicated for the treatment of generalized anxiety disorder (gad). the efficacy of duloxetine was established in three short-term trials and one maintenance trial in adults [see clinical studies

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

medsource pharmaceuticals - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - duloxetine delayed-release capsules are indicated for the treatment of major depressive disorder (mdd). the efficacy of duloxetine was established in four short term and one maintenance trial in adults [see clinical studies (14.1) ]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. duloxetine delayed-release capsules are indicated for the treatment of generalized anxiety disorder (gad). the efficacy of duloxetine was established in three short-term trials and one maintenance trial in adults [see ]. duloxetine